First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

Liu, Tianshu; Bai, Y.; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, H.; Bai, C.; Bai, L.; Cheng, Ying; Zhang, Jingdong; Zhong, H.; Ba, Y.; Hu, Wen-Wei; Xu, R.; Guo, Weijian; Qin, S.; Yang, N.; Lu, Jianwei; Shitara, K.; Lei, M.; Li, Mingshun; Bao, Nicole; Chen, Tian; Shen, L.

doi:10.1002/ijc.34296

Public

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

Shared by NobleBlocks on Sep 19, 2022 • 12:00 AM UTC

Authors:

Tianshu Liu

Y. Bai

Xiaoyan Lin

Abstract

First‐line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)‐negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 64...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!